Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 6, 2016, Pages 3563-3578

  Serre, Stéphanie B N ^a   Jensen, Sanne B ^a   Ghanem, Lubna ^a   Humes, Daryl G ^a   Ramirez, Santseharay ^a   Li, Yi Ping ^a,c   Krarup, Henrik ^b   Bukh, Jens ^a   Gottwein, Judith M ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; DELDEPREVIR; FALDAPREVIR; GRAZOPREVIR; NONSTRUCTURAL PROTEIN 3; PARITAPREVIR; PROTEINASE INHIBITOR; SIMEPREVIR; TELAPREVIR; VANIPREVIR; ANTIVIRUS AGENT; NS3 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

5' UNTRANSLATED REGION; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; CONCENTRATION RESPONSE; CROSS RESISTANCE; EC50; GENETIC STABILITY; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; IN VITRO SELECTION; IN VITRO STUDY; LIFE CYCLE; NONHUMAN; PRIORITY JOURNAL; REVERSE GENETICS; VIRUS REPLICATION; VIRUS TRANSCRIPTION; ANTAGONISTS AND INHIBITORS; CLASSIFICATION; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C; HUMAN; MULTIDRUG RESISTANCE; TUMOR CELL LINE; VIROLOGY;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE, VIRAL; HEPACIVIRUS; HEPATITIS C; HUMANS; PROTEASE INHIBITORS; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84973643890     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02929-15     Document Type: Article

References (87)

1. Hajarizadeh B, Grebely J, Dore GJ. 2013. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 10:553-562. http://dx.doi.org/10.1038/nrgastro.2013.107.
2. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. 2014. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61:S45-S57. http://dx.doi.org/10.1016/j.jhep.2014.07.027.
3. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. 2014. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59:318 -327. http://dx.doi.org/10.1002/hep.26744.
4. Sarrazin C. 2016. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol 64:486 -504. http://dx.doi .org/10.1016/j.jhep.2015.09.011.
5. Pawlotsky JM. 2015. Hepatitis C treatment: the data flood goes on-an update from the liver meeting 2014. Gastroenterology 148:468 - 479. http: //dx.doi.org/10.1053/j.gastro.2015.01.002.
6. Pawlotsky JM. 2014. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 146:1176 -1192. http://dx.doi.org/10 .1053/j.gastro.2014.03.003.
7. Antaki N, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S, Gadano A, Zein N, Lai CL, Pawlotsky JM, Heathcote EJ, Dusheiko G, Marcellin P. 2010. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int 30:342-355. http://dx.doi.org/10 .1111/j.1478-3231.2009.02188.x.
8. Lontok E, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O, McPhee F, Mo H, Parkin N, Pilot-Matias T, Miller V. 2015. Hepatitis C virus drug resistance-associated substitutions: state of the art summary. Hepatology 62:1623-1632. http://dx.doi.org/10.1002/hep.27934.
9. Bartenschlager R, Lohmann V, Penin F. 2013. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol 11:482-496. http://dx.doi.org/10.1038/nrmicro3046.
10. Vermehren J, Sarrazin C. 2012. The role of resistance in HCV treatment. Best Pract Res Clin Gastroenterol 26:487-503. http://dx.doi.org/10.1016/j .bpg.2012.09.011.
11. Gottwein JM, Bukh J. 2008. Cutting the Gordian knot- development and biological relevance of hepatitis C virus cell culture systems. Adv Virus Res 71:51-133. http://dx.doi.org/10.1016/S0065-3527(08)00002-X.
12. Lindenbach BD. 2013. Virion assembly and release. Curr Top Microbiol Immunol 369:199 -218. http://dx.doi.org/10.1007/978-3-642-27340-7-8.
13. Jones DM, Atoom AM, Zhang X, Kottilil S, Russell RS. 2011. A genetic interaction between the core and NS3 proteins of hepatitis C virus is essential for production of infectious virus. J Virol 85:12351-12361. http: //dx.doi.org/10.1128/JVI.05313-11.
14. Mousseau G, Kota S, Takahashi V, Frick DN, Strosberg AD. 2011. Dimerization-driven interaction of hepatitis C virus core protein with NS3 helicase. J Gen Virol 92:101-111. http://dx.doi.org/10.1099/vir.0 .023325-0.
15. Kohlway A, Pirakitikulr N, Barrera FN, Potapova O, Engelman DM, Pyle AM, Lindenbach BD. 2014. Hepatitis C virus RNA replication and virus particle assembly require specific dimerization of the NS4A protein transmembrane domain. J Virol 88:628 - 642. http://dx.doi.org/10.1128 /JVI.02052-13.
16. Aydin C, Mukherjee S, Hanson AM, Frick DN, Schiffer CA. 2013. The interdomain interface in bifunctional enzyme protein 3/4A (NS3/4A) regulates protease and helicase activities. Protein Sci 22:1786 -1798. http://dx .doi.org/10.1002/pro.2378.
17. Neddermann P, Clementi A, De Francesco R. 1999. Hyperphosphorylation of the hepatitis C virus NS5A protein requires an active NS3 protease, NS4A, NS4B, and NS5A encoded on the same polyprotein. J Virol 73:9984 -9991.
18. Scheel TK, Rice CM. 2013. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 19:837-849. http: //dx.doi.org/10.1038/nm.3248.
19. Bukh J, Meuleman P, Tellier R, Engle RE, Feinstone SM, Eder G, Satterfield WC, Govindarajan S, Krawczynski K, Miller RH, Leroux-Roels G, Purcell RH. 2010. Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models. J Infect Dis 201:1381-1389. http://dx.doi.org/10.1086/651579.
20. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626. http://dx.doi.org/10.1126/science.1114016.
21. Gottwein JM, Scheel TK, Jensen TB, Ghanem L, Bukh J. 2011. Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Gastroenterology 141:1067-1079. http://dx.doi.org/10.1053/j.gastro.2011.06.004.
22. Li YP, Ramirez S, Humes D, Jensen SB, Gottwein JM, Bukh J. 2014. Differential sensitivity of 5=UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors. Gastroenterology 146: 812-821. http://dx.doi.org/10.1053/j.gastro.2013.11.009.
23. Li YP, Ramirez S, Jensen SB, Purcell RH, Gottwein JM, Bukh J. 2012. Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system. Proc Natl Acad Sci U S A109:19757-19762. http://dx .doi.org/10.1073/pnas.1218260109.
24. Blight KJ, McKeating JA, Rice CM. 2002. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 76: 13001-13014. http://dx.doi.org/10.1128/JVI.76.24.13001-13014.2002.
25. Gottwein JM, Scheel TK, Hoegh AM, Lademann JB, Eugen-Olsen J, Lisby G, Bukh J. 2007. Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses. Gastroenterology 133:1614 -1626. http://dx.doi.org/10.1053/j.gastro.2007.08.005.
26. Gottwein JM, Scheel TK, Callendret B, Li YP, Eccleston HB, Engle RE, Govindarajan S, Satterfield W, Purcell RH, Walker CM, Bukh J. 2010. Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies. J Virol 84:5277-5293. http://dx.doi.org/10.1128/JVI.02667-09.
27. Scheel TK, Gottwein JM, Mikkelsen LS, Jensen TB, Bukh J. 2011. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-alpha. Gastroenterology 140:1032-1042. http://dx.doi.org/10.1053/j.gastro.2010.11.036.
28. Jensen SB, Serre SB, Humes DG, Ramirez S, Li YP, Bukh J, Gottwein JM. 2015. Substitutions at NS3 residue 155, 156, or 168 of hepatitis C virus genotypes 2 to 6 induce complex patterns of protease inhibitor resistance. Antimicrob Agents Chemother 59:7426 -7436. http://dx.doi.org/10.1128 /AAC.01953-15.
29. Kuiken C, Combet C, Bukh J, Shin I, Deleage G, Mizokami M, Richardson R, Sablon E, Yusim K, Pawlotsky JM, Simmonds P. 2006. A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes. Hepatology 44:1355-1361. http://dx.doi.org/10.1002 /hep.21377.
30. Russell RS, Meunier JC, Takikawa S, Faulk K, Engle RE, Bukh J, Purcell RH, Emerson SU. 2008. Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus. Proc Natl Acad Sci U S A 105:4370 - 4375. http://dx.doi.org/10.1073/pnas.0800422105.
31. Serre SB, Krarup HB, Bukh J, Gottwein JM. 2013. Identification of alpha interferon-induced envelope mutations of hepatitis C virus in vitro associated with increased viral fitness and interferon resistance. J Virol 87: 12776 -12793. http://dx.doi.org/10.1128/JVI.00901-13.
32. Kieffer TL, De Meyer S, Bartels DJ, Sullivan JC, Zhang EZ, Tigges A, Dierynck I, Spanks J, Dorrian J, Jiang M, Adiwijaya B, Ghys A, Beumont M, Kauffman RS, Adda N, Jacobson IM, Sherman KE, Zeuzem S, Kwong AD, Picchio G. 2012. Hepatitis C viral evolution in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevirbased therapy in clinical trials. PLoS One 7:e34372. http://dx.doi.org/10 .1371/journal.pone.0034372.
33. Susser S, Vermehren J, Forestier N, Welker MW, Grigorian N, Fuller C, Perner D, Zeuzem S, Sarrazin C. 2011. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J Clin Virol 52:321-327. http://dx .doi.org/10.1016/j.jcv.2011.08.015.
34. Lin C, Gates CA, Rao BG, Brennan DL, Fulghum JR, Luong YP, Frantz JD, Lin K, Ma S, Wei YY, Perni RB, Kwong AD. 2005. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 280:36784 -36791. http: //dx.doi.org/10.1074/jbc.M506462200.
35. Yi M, Tong X, Skelton A, Chase R, Chen T, Prongay A, Bogen SL, Saksena AK, Njoroge FG, Veselenak RL, Pyles RB, Bourne N, Malcolm BA, Lemon SM. 2006. Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations. J Biol Chem 281:8205-8215. http://dx.doi.org/10.1074/jbc.M510246200.
36. Jiang M, Mani N, Lin C, Ardzinski A, Nelson M, Reagan D, Bartels D, Zhou Y, Nicolas O, Rao BG, Muh U, Hanzelka B, Tigges A, Rijnbrand R, Kieffer TL. 2013. In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir. Antimicrob Agents Chemother 57:6236 - 6245. http://dx.doi.org/10.1128 /AAC.01578-13.
37. Shimakami T, Welsch C, Yamane D, McGivern DR, Yi M, Zeuzem S, Lemon SM. 2011. Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus. Gastroenterology 140:667-675. http://dx.doi.org/10.1053/j.gastro.2010.10 .056.
38. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin C, Weegink C, Reesink H, Zeuzem S, Kwong AD. 2007. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132:1767-1777. http://dx.doi.org/10.1053/j.gastro .2007.02.037.
39. Summa V, Ludmerer SW, McCauley JA, Fandozzi C, Burlein C, Claudio G, Coleman PJ, Dimuzio JM, Ferrara M, Di Filippo M, Gates AT, Graham DJ, Harper S, Hazuda DJ, McHale C, Monteagudo E, Pucci V, Rowley M, Rudd MT, Soriano A, Stahlhut MW, Vacca JP, Olsen DB, Liverton NJ, Carroll SS. 2012. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 56:4161- 4167. http://dx.doi.org /10.1128/AAC.00324-12.
40. Lohmann V, Bartenschlager R. 2014. On the history of hepatitis C virus cell culture systems. J Med Chem 57:1627-1642. http://dx.doi.org/10 .1021/jm401401n.
41. Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, Mizokami M, Wakita T. 2003. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125:1808 -1817. http://dx.doi.org /10.1053/j.gastro.2003.09.023.
42. Saeed M, Scheel TK, Gottwein JM, Marukian S, Dustin LB, Bukh J, Rice CM. 2012. Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells. Antimicrob Agents Chemother 56: 5365-5373. http://dx.doi.org/10.1128/AAC.01256-12.
43. Peng B, Yu M, Xu S, Lee YJ, Tian Y, Yang H, Chan K, Mo H, McHutchison J, Delaney W, Cheng G. 2013. Development of robust hepatitis C virus genotype 4 subgenomic replicons. Gastroenterology 144: 59 - 61. http://dx.doi.org/10.1053/j.gastro.2012.09.033.
44. Saeed M, Gondeau C, Hmwe S, Yokokawa H, Date T, Suzuki T, Kato T, Maurel P, Wakita T. 2013. Replication of hepatitis C virus genotype 3a in cultured cells. Gastroenterology 144:56 -58. http://dx.doi.org/10.1053 /j.gastro.2012.09.017.
45. Yu M, Peng B, Chan K, Gong R, Yang H, Delaney W, Cheng G. 2014. Robust and persistent replication of the genotype 6a hepatitis C virus replicon in cell culture. Antimicrob Agents Chemother 58:2638 -2646. http://dx.doi.org/10.1128/AAC.01780-13.
46. Wose Kinge CN, Espiritu C, Prabdial-Sing N, Sithebe NP, Saeed M, Rice CM. 2014. Hepatitis C virus genotype 5a subgenomic replicons for evaluation of direct-acting antiviral agents. Antimicrob Agents Chemother 58:5386 -5394. http://dx.doi.org/10.1128/AAC.03534-14.
47. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, Bartenschlager R, Liang TJ. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11:791-796. http://dx.doi .org/10.1038/nm1268.
48. Li YP, Ramirez S, Gottwein JM, Scheel TK, Mikkelsen L, Purcell RH, Bukh J. 2012. Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains. Proc Natl Acad SciUSA109:E1101-E1110. http://dx.doi.org/10.1073/pnas.1203829109.
49. Ramirez S, Li YP, Jensen SB, Pedersen J, Gottwein JM, Bukh J. 2014. Highly efficient infectious cell culture of three HCV genotype 2b strains and sensitivity to lead protease, NS5A, and polymerase inhibitors. Hepatology 59:395- 407. http://dx.doi.org/10.1002/hep.26660.
50. Imhof I, Simmonds P. 2010. Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6. J Virol 84:4597- 4610. http://dx.doi.org/10.1128/JVI.02698-09.
51. Imhof I, Simmonds P. 2011. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). Hepatology 53:1090 -1099. http://dx.doi.org/10.1002/hep.24172.
52. Lenz O, Verbinnen T, Lin TI, Vijgen L, Cummings MD, Lindberg J, Berke JM, Dehertogh P, Fransen E, Scholliers A, Vermeiren K, Ivens T, Raboisson P, Edlund M, Storm S, Vrang L, de Kock H, Fanning GC, Simmen KA. 2010. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 54: 1878 -1887. http://dx.doi.org/10.1128/AAC.01452-09.
53. Cheng G, Chan K, Yang H, Corsa A, Pokrovskii M, Paulson M, Bahador G, Zhong W, Delaney W. 2011. Selection of clinically relevant protease inhibitor-resistant viruses using the genotype 2a hepatitis C virus infection system. Antimicrob Agents Chemother 55:2197-2205. http://dx.doi .org/10.1128/AAC.01382-10.
54. Foster GR, Hézode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, van Heeswijk R, van Baelen B, Picchio G, Beumont M. 2011. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 141:881- 889. http://dx.doi.org/10.1053/j.gastro.2011.05.046.
55. De Meyer S, Ghys A, Foster GR, Beumont M, Van Baelen B, Lin TI, Dierynck I, Ceulemans H, Picchio G. 2013. Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes. J Viral Hepat 20:395-403. http://dx.doi.org/10.1111/jvh.12046.
56. Gottwein JM, Jensen SB, Li YP, Ghanem L, Scheel TK, Serre SB, Mikkelsen L, Bukh J. 2013. Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses. Antimicrob Agents Chemother 57:1291-1303. http: //dx.doi.org/10.1128/AAC.02164-12.
57. Lenz O, Vijgen L, Berke JM, Cummings MD, Fevery B, Peeters M, De Smedt G, Moreno C, Picchio G. 2013. Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202). J Hepatol 58:445-451. http://dx.doi.org/10.1016 /j.jhep.2012.10.028.
58. Silva MO, Treitel M, Graham DJ, Curry S, Frontera MJ, McMonagle P, Gupta S, Hughes E, Chase R, Lahser F, Barnard RJ, Howe AY, Howe JA. 2013. Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3. J Hepatol 59:31-37. http: //dx.doi.org/10.1016/j.jhep.2013.02.018.
59. Bronowicki JP, Ratziu V, Gadano A, Thuluvath PJ, Bessone F, Martorell CT, Pol S, Terg R, Younes Z, He B, Eley T, Cohen D, Yu F, Hernandez D, McPhee F, Mendez P, Hughes E. 2014. Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. J Hepatol 61:1220 -1227. http: //dx.doi.org/10.1016/j.jhep.2014.07.011.
60. Lawitz E, Sullivan G, Rodriguez-Torres M, Bennett M, Poordad F, Kapoor M, Badri P, Campbell A, Rodrigues L, Jr, Hu Y, Pilot-Matias T, Vilchez RA. 2015. Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection. J Infect 70:197-205. http://dx.doi.org/10.1016/j.jinf.2014.09.008.
61. Chayama K, Notsumata K, Kurosaki M, Sato K, Rodrigues L, Jr, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Kumada H. 2015. Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients. Hepatology 61: 1523-1532. http://dx.doi.org/10.1002/hep.27705.
62. Moreno C, Hézode C, Marcellin P, Bourgeois S, Francque S, Samuel D, Zoulim F, Grange JD, Shukla U, Lenz O, Ouwerkerk-Mahadevan S, Fevery B, Peeters M, Beumont M, Jessner W. 2015. Efficacy and safety of simeprevir with PegIFN/ribavirin in naive or experienced patients infected with chronic HCV genotype 4. J Hepatol 62:1047-1055. http://dx .doi.org/10.1016/j.jhep.2014.12.031.
63. Hézode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, Marcellin P, Hall C, Schnell G, Pilot-Matias T, Mobashery N, Redman R, Vilchez RA, Pol S. 2015. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatmentexperienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 385:2502-2509. http: //dx.doi.org/10.1016/S0140-6736(15)60159-3.
64. Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ari ZB, Zhao Y, Brown DD, Wan S, DiNubile MJ, Nguyen BY, Robertson MN, Wahl J, Barr E, Butterton JR. 2015. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 163:1-13. http://dx.doi.org/10.7326/M15-0785.
65. Kumada H, Sato K, Takehara T, Nakamuta M, Ishigami M, Chayama K, Toyota J, Suzuki F, Nakayasu Y, Ochi M, Yamada I, Okanoue T. 2015. Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan. Hepatol Res 45:745-754. http://dx.doi.org/10.1111/hepr.12416.
66. Kuiken C, Hraber P, Thurmond J, Yusim K. 2008. The hepatitis C sequence database in Los Alamos. Nucleic Acids Res 36:D512-D516. http: //dx.doi.org/10.1093/nar/gkm962.
67. Gottwein JM, Jensen SB, Serre SB, Ghanem L, Scheel TK, Jensen TB, Krarup H, Uzcategui N, Mikkelsen LS, Bukh J. 2013. Adapted J6/JFH1-based hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitor. Antimicrob Agents Chemother 57:6034 - 6049. http://dx.doi.org/10.1128/AAC.01176-13.
68. Franco S, Tural C, Nevot M, Molto J, Rockstroh JK, Clotet B, Martinez MA. 2014. Detection of a sexually transmitted hepatitis C virus protease inhibitor-resistance variant in a human immunodeficiency virus-infected homosexual man. Gastroenterology 147:599 - 601. http://dx.doi.org/10 .1053/j.gastro.2014.05.010.
69. De Meyer S, Dierynck I, Ghys A, Beumont M, Daems B, Van Baelen B, Sullivan JC, Bartels DJ, Kieffer TL, Zeuzem S, Picchio G. 2012. Char-acterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial. Hepatology 56:2106 -2115. http://dx.doi.org/10.1002/hep.25962.
70. Pietschmann T, Zayas M, Meuleman P, Long G, Appel N, Koutsoudakis G, Kallis S, Leroux-Roels G, Lohmann V, Bartenschlager R. 2009. Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations. PLoS Pathog 5:e1000475. http://dx.doi.org/10.1371/journal.ppat.1000475.
71. Yamane D, McGivern DR, Wauthier E, Yi M, Madden VJ, Welsch C, Antes I, Wen Y, Chugh PE, McGee CE, Widman DG, Misumi I, Bandyopadhyay S, Kim S, Shimakami T, Oikawa T, Whitmire JK, Heise MT, Dittmer DP, Kao CC, Pitson SM, Merrill AH, Jr, Reid LM, Lemon SM. 2014. Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation. Nat Med 20:927-935. http://dx.doi.org/10.1038 /nm.3610.
72. Saeed M, Andreo U, Chung HY, Espiritu C, Branch AD, Silva JM, Rice CM. 2015. SEC14L2 enables pan-genotype HCV replication in cell culture. Nature 524:471-475. http://dx.doi.org/10.1038/nature14899.
73. Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA. 2006. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 70:28 -38. http: //dx.doi.org/10.1016/j.antiviral.2005.12.003.
74. He Y, King MS, Kempf DJ, Lu L, Lim HB, Krishnan P, Kati W, Middleton T, Molla A. 2008. Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system. Antimicrob Agents Chemother 52:1101-1110. http://dx.doi.org/10.1128/AAC .01149-07.
75. Zhou Y, Muh U, Hanzelka BL, Bartels DJ, Wei Y, Rao BG, Brennan DL, Tigges AM, Swenson L, Kwong AD, Lin C. 2007. Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha. J Biol Chem 282:22619 -22628. http://dx.doi.org/10.1074/jbc.M610207200.
76. Zhou Y, Bartels DJ, Hanzelka BL, Muh U, Wei Y, Chu HM, Tigges AM, Brennan DL, Rao BG, Swenson L, Kwong AD, Lin C. 2008. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 52:110 -120. http://dx.doi .org/10.1128/AAC.00863-07.
77. Brass V, Berke JM, Montserret R, Blum HE, Penin F, Moradpour D. 2008. Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3-4A complex. Proc Natl Acad Sci USA105:14545-14550. http://dx.doi.org/10.1073/pnas.0807298105.
78. Paolucci S, Fiorina L, Piralla A, Gulminetti R, Novati S, Barbarini G, Sacchi P, Gatti M, Dossena L, Baldanti F. 2012. Naturally occurring mutations to HCV protease inhibitors in treatment-naive patients. Virol J 9:245. http://dx.doi.org/10.1186/1743-422X-9-245.
79. Susser S, Welsch C, Wang Y, Zettler M, Domingues FS, Karey U, Hughes E, Ralston R, Tong X, Herrmann E, Zeuzem S, Sarrazin C. 2009. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 50:1709 -1718. http://dx .doi.org/10.1002/hep.23192.
80. Sølund C, Krarup H, Ramirez S, Thielsen P, Røge BT, Lunding S, Barfod TS, Madsen LG, Tarp B, Christensen PB, Gerstoft J, Laursen AL, Bukh J, Weis N. 2014. Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations. PLoS One 9:e113034. http://dx.doi.org/10 .1371/journal.pone.0113034.
81. Kim JL, Morgenstern KA, Lin C, Fox T, Dwyer MD, Landro JA, Chambers SP, Markland W, Lepre CA, O'Malley ET, Harbeson SL, Rice CM, Murcko MA, Caron PR, Thomson JA. 1996. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87:343-355. http://dx.doi.org/10.1016/S0092 -8674(00)81351-3.
82. Love RA, Parge HE, Wickersham JA, Hostomsky Z, Habuka N, Moomaw EW, Adachi T, Hostomska Z. 1996. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 87:331-342. http://dx.doi.org/10.1016/S0092 -8674(00)81350-1.
83. Romano KP, Ali A, Aydin C, Soumana D, Ozen A, Deveau LM, Silver C, Cao H, Newton A, Petropoulos CJ, Huang W, Schiffer CA. 2012. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog 8:e1002832. http://dx.doi.org/10.1371 /journal.ppat.1002832.
84. Lim SR, Qin X, Susser S, Nicholas JB, Lange C, Herrmann E, Hong J, Arfsten A, Hooi L, Bradford W, Najera I, Smith P, Zeuzem S, Kossen K, Sarrazin C, Seiwert SD. 2012. Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution. Antimicrob Agents Chemother 56:271-279. http://dx.doi.org/10.1128/AAC.05636-11.
85. McGivern DR, Masaki T, Lovell W, Hamlett C, Saalau-Bethell S, Graham B. 2015. Protease inhibitors block multiple functions of the NS3/4A protease-helicase during the hepatitis C virus life cycle. J Virol 89:5362-5370. http://dx.doi.org/10.1128/JVI.03188-14.
86. Welsch C, Shimakami T, Hartmann C, Yang Y, Domingues FS, Lengauer T, Zeuzem S, Lemon SM. 2012. Peptidomimetic escape mechanisms arise via genetic diversity in the ligand-binding site of the hepatitis C virus NS3/4A serine protease. Gastroenterology 142:654 - 663. http://dx .doi.org/10.1053/j.gastro.2011.11.035.
87. Rimmert B, Sabet S, Ackad E, Yousef MS. 2014. A 3D structural model and dynamics of hepatitis C virus NS3/4A protease (genotype 4a, strain ED43) suggest conformational instability of the catalytic triad: implications in catalysis and drug resistivity. J Biomol Struct Dyn 32:950 -958. http://dx.doi.org/10.1080/07391102.2013.800001.